Ark’s vision is to create a world without late-stage cancer through the introduction of accurate, affordable, and actionable cancer detection blood tests.

About Ark

Ark is an end-to-end solution provider focused on cancer early detection. By harnessing advanced data science and proprietary miRNA detection technology, Ark develops non-invasive and cost-effective blood tests to detect early stage cancers before clinical symptoms appear. The company collaborates extensively with top medical research institutions globally and is spearheading Asia’s largest miRNA clinical studies targeting more than 50,000 participants. Ark is headquartered in Singapore, with R&D, manufacturing and clinical diagnostic operations in China and USA.

Ark was founded in early 2018 through the merger of MiRXES, a privately-held life sciences company which had developed a highly sensitive and robust miRNA detection technology and identified novel blood-borne cancer biomarkers, and Venturecraft, Southeast Asia’s leading venture capital firm focused on MedTech, BioTech, and Digital Health.

Isaac Ho

Isaac Ho, co-Founder & co-CEO

Having founded Singapore Health, a medical health care services provider, and subsequently, Venturecraft Group, Isaac is a proven veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Programme for Biomedical Sciences.

Isaac is most passionate communicator and marketeer. Most notably, Isaac has developed a strong and extensive China distribution network with private and government agencies, and he has assisted many Singaporean and global companies in navigating China’s market. Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Isaac Ho

Isaac Ho, co-Founder & co-CEO

Having founded Singapore Health, a medical health care services provider, and subsequently, Venturecraft Group, Isaac is a proven veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Programme for Biomedical Sciences.

Isaac is most passionate communicator and marketeer. Most notably, Isaac has developed a strong and extensive China distribution network with private and government agencies, and he has assisted many Singaporean and global companies in navigating China’s market. Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Leadership

Isaac Ho, co-Founder & co-CEO

Isaac Ho

co-Founder & co-CEO

Having founded Singapore Health, a medical health care services provider, and subsequently, Venturecraft Group, Isaac is a proven veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Programme for Biomedical Sciences.

Isaac is most passionate communicator and marketeer. Most notably, Isaac has developed a strong and extensive China distribution network with private and government agencies, and he has assisted many Singaporean and global companies in navigating China’s market. Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Zhou Lihan, co-Founder & co-CEO

Zhou Lihan

co-Founder & co-CEO

In 2014, Lihan co-founded and served as CEO of MiRXES, a biotech startup developing microRNA technologies and cancer detection tests. He oversaw MiRXES’ operations in Singapore and China, and managed collaborations with leading clinical consortia and pharmaceutical companies in developing microRNA based diagnostic assays. Lihan was recently recognized by the MIT Technology Review as a member of the Innovators Under 35. MIRXES was recognized as Singapore’s Most Promising Startup 2016 by the Emerging Enterprise Award. Prior to founding MiRXES, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel miRNA qPCR assay platform and an integrated workflow for biomarker discovery. Lihan has a PhD in Biochemistry from the National University of Singapore. Lihan has authored and co-authored more than 20 peer-reviewed publications and 8 patent applications.

Zou Ruiyang, co-Founder & CTO

Zou Ruiyang

co-Founder & CTO

Ruiyang is primarily credited for Ark’s core miRNA technology and know-how. He oversees the diagnostic test development and Ark’s global research and development. Prior to Ark, Ruiyang is one of the co-founders of MiRXES, and was the Head of Bioinformatics at A*STAR’s MicroRNA Signature Identification Center. He co-authored more than ten publications and has eight patents and applications.

Ruiyang has a PhD in Chemical and Pharmaceutical Engineering from the Singapore-MIT Alliance, which is an engineering and life science educational and research collaboration the National University of Singapore (NUS), the Nanyang Technological University (NTU), and the Massachusetts Institute of Technology (MIT). Ruiyang also has Bachelors in Engineering and another in Science from Nankai University and Tianjin University, respectively.

Ong Jeong Shing, CIO

Ong Jeong Shing

Chief Investment Officer

Jeong Shing oversees Ark’s investments and external alliance activities. He was the Investment Director at Venturecraft. Jeong Shing was instrumental in helping Venturecraft grow into an established global VC fund, and made crucial investment strategies to specialise in Biotech, Medtech and Digital Health solutions in the US, China and Southeast Asia. Jeong Shing holds an MBA from Cambridge Judge Business School and a B.Eng in Chemical and Bioengineering from the National University of Singapore.

Cheng He, AVP, Research & Development
nopic

Cheng He

AVP, Research & Development

Cheng He leads Ark’s research and development. Since his time at MirXes, and now Ark, Cheng He has continued to lead the discovery of new microRNA biomarkers in tissue, cell and biofluid and productized cell-free microRNA biomarkers into liquid biopsy assay. Cheng He strives to solve healthcare problems with innovative technologies and has worked on multi-disciplinary fields including the development of nanowire sensors and mRNA clinical assay for cancer prognosis. Cheng He holds a PhD in Electrical Engineering from National University of Singapore, Master in Material Science from MIT and a Bachelor in Bioengineering from Nanyang Technological University.

Jeremiah Decosta, AVP, Singapore Manufacturing Operation

Jeremiah Decosta

AVP, Singapore Manufacturing Operation

Jeremiah oversees production, supply chain and quality control for the Singapore operation. Having held key positions including Production Director and Head of Operations at both MNCs and start-ups, Jeremiah comes with highly relevant career experiences, including in Quality Assurance, scale-up manufacturing operations and tech transfer across multiple product lines, where he specialises in vitro diagnostics (IVD) medical device industry. Jeremiah holds a Bachelor’s Degree in Biomedical Science from the University of Bradford, UK.

Zhou Qiumei, AVP, China Manufacturing Operation

Zhou Qiumei

AVP, China Manufacturing Operation

Qiumei oversees Ark’s manufacturing operations in China. With more than 10 years of experience in R&D, production and quality management in the biomedical industry, Qiumei is a veteran in ISO13485, CE and cFDA quality and regulatory framework for medical devices. Qiumei has a Masters degree in Biochemistry and Molecular Biology.

Tu Jing, AVP, Commercial Operations

Tu Jing

AVP, Commercial Operations

Tu Jing is responsible for commercial operations. Tu Jing is a veteran in the Medtech and pharmaceuticals industries with over 20 years of experience, including as the nation-wide General Manager, Marketing Director, Sales Director of several publicly-listed companies, and had participated developing in their marketing strategy and planning.

Holly Fang, AVP, Strategy & Key Accounts

Holly Fang

AVP, Strategy & Key Accounts

Holly oversees marketing  strategy and key accounts. Prior to Ark, Holly led Strategic Partnerships for Asia Pacific at App Annie, Inc, the San Francisco-based global leader in market data and insights on the app economy. Previously, Holly was the Assistant Head of the Infocomms & Media division at the Singapore Economic Development Board, helping to grow direct investments from top technology companies in Singapore. Holly holds a BSc in Economics from Duke University.

Claire Liu, AVP, Digital Marketing

Claire Liu

AVP, Digital Marketing

Claire is responsible for digital marketing. Prior to Ark, Claire oversaw user system operations in Alibaba, 58 City and Dangdang, leading teams to build business ecosystems and meeting companies’ desired performance targets. She once worked at the Beijing TV Station as the Director of the Life Channel, focusing on medical health. She has an Executive MBA from the University of Texas.

Ma Tao, AVP, Corporate Affairs

Ma Tao

AVP, Corporate Affairs

Ma Tao has more than ten years of experience in sales and marketing and managed top-performing teams at multinational medical device companies including Johnson & Johnson and Boston Scientific. As a co-founder of a CTC start-up, he assisted the research team from the Chinese Academy of Sciences in product prototyping, manufacturing site setup, product registration and launch. Ma Tao has an MBA from the Guanghua School of Management, Peking University, and received a Master’s degree in Biomedical Engineering from the same university.

Ethan Zhai, Senior Director of People

Ethan Zhai

Senior Director of People

Ethan is responsible for Ark’s human resources. With 13 years of experience in human resources, Ethan had worked for Tianjin Foreign Enterprises & Experts Service (TJ-FESCO), IT services provider CTG Group, and served as the General Manager and Business Director at the branch of Sino-Singapore Tianjin Eco-city. He has provided human resource services for major corporations such as PricewaterhouseCoopers (PwC), OTIS Elevator and Internet services company Sohu.

Board of Directors

Too Heng-Phon, Chairman

Professor Too Heng-Phon

Chairman

Professor Too Heng-Phon received his undergraduate training in Biochemistry, Imperial College of Science & Technology, UK. He then continued with his PhD training in a joint research project in Imperial College, Institute of Ophthalmology and West Minister Hospital, London. Currently, he is a faculty in the Department of Biochemistry, National University Singapore, a Principal Scientist in the Bioprocess Technological Institute. His laboratory was funded by Roche Diagnostics (USA & Asia Pacific) and National Institute of Health (USA) to develop qPCR assays for infectious diseases. He is an awardee of a number of Commercialization of Technology grants from A*STAR and Singapore-Massachusetts Research & Technology (SMART). He has intellectual property protections on specific diagnostic platforms with various departments and with Massachusetts Institute of Technology, USA. He is collaborating with a number of clinical groups locally and globally on discovery and development of microRNA biomarkers.

Isaac Ho

Isaac Ho

co-Founder & co-CEO

Having founded Singapore Health, a medical health care services provider, and subsequently, VentureCraft Group, Isaac is a proven veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Programme for Biomedical Sciences.

Isaac is most passionate communicator and marketeer. Most notably, Isaac has developed a strong and extensive China distribution network with private and government agencies, and he has assisted many Singaporean and global companies in navigating China’s market. Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Zhou Lihan

Zhou Lihan

co-Founder & co-CEO

In 2014, Lihan co-founded and served as CEO of MiRXES, a biotech startup developing microRNA technologies and cancer detection tests. He oversaw MiRXES’ operations in Singapore and China, and managed collaborations with leading clinical consortia and pharmaceutical companies in developing microRNA based diagnostic assays. Lihan was recently recognized by the MIT Technology Review as a member of the Innovators Under 35. MIRXES was recognized as Singapore’s Most Promising Startup 2016 by the Emerging Enterprise Award. Prior to founding MiRXES, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform and an integrated workflow for biomarker discovery. Lihan has a PhD in Biochemistry from the National University of Singapore. Lihan has authored and co-authored more than 20 peer-reviewed publications and 8 patent applications.

Zou Ruiyang

Zou Ruiyang

co-Founder & CTO

Ruiyang is primarily credited for Ark’s core miRNA technology and know-how. He oversees the diagnostic test development and Ark’s global research and development. Prior to Ark, Ruiyang is one of the co-founders of MiRXES, and was the Head of Bioinformatics at A*STAR’s MicroRNA Signature Identification Center. He co-authored more than ten publications and has eight patents and applications.

Ruiyang has a PhD in Chemical and Pharmaceutical Engineering from the Singapore-MIT Alliance, which is an engineering and life science educational and research collaboration the National University of Singapore (NUS), the Nanyang Technological University (NTU), and the Massachusetts Institute of Technology (MIT). Ruiyang also has Bachelors in Engineering and another in Science from Nankai University and Tianjin University, respectively.

Scientific Advisory Board

Professor Yeoh KG, M.D. Dean, NUS Medical School

Professor Yeoh KG

M.D. Dean, NUS Medical School

A gastroenterologist by training, Assoc Prof Yeoh Khay Guan (MBBS, MMed, FRCP) is Deputy Chief Executive of the National University Health System (NUHS) as well as Dean of the NUS Yong Loo Lin School of Medicine. He is also Senior Consultant with the Department of Gastroenterology, National University Hospital. Assoc Prof Yeoh’s research interest is in the early detection of gastric and colorectal cancers, and has published over 100 peer-reviewed papers in international journals. He is the Lead Principal Investigator of the Singapore Gastric Cancer Consortium, a national flagship research group and, he is the chairman of the National Colorectal Cancer Screening Committee of the Health Promotion Board.

Professor Frank Slack, M.D. S.W Mallinckrodt Professor, Harvard Medical School

Professor Frank Slack

M.D. S.W Mallinckrodt Professor, Harvard Medical School

Dr. Frank Slack is the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, Beth Israel Deaconess Medical Center at Harvard Medical School. He received his BSc from the University of Cape Town in South Africa before completing his PhD in molecular biology at Tufts University School of Medicine. He began work on microRNAs as a postdoctoral fellow in Gary Ruvkun’s laboratory at Harvard Medical School, where he co-discovered the second known microRNA, let-7. The Slack laboratory is at the forefront of the small RNA revolution. They co-discovered the first human microRNA, let-7 and showed that it is a tumor suppressor that controls key cancer genes. Their research also extends to discovery of additional novel small RNAs in development, cancer, aging and diabetes as well as identifying novel SNPs in the non-coding portions of the genome with an eye to identifying the next generation of actionable targets in cancer.

Alex Matter, M.D. CEO, A*STAR ETC

Alex Matter

M.D. CEO, A*STAR ETC

Dr Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. He played an important role in the success of several anticancer drugs. He has published more than 100 scientific articles and several book chapters in the area of oncology and haematology. He is emeritus Professor of the Medical Faculty of the University Basel and an Honorary Adjunct Professor of the Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore. Dr. Matter is the recipient of the Life-time Achievement Award from IBC Life Sciences, the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award. Recently he was awarded the 2013 Szent-Györgyi Prize from the US National Foundation for Cancer Research.

Lam Kong Peng, PH.D. Executive Director, A*STAR BTI

Lam Kong Peng

Ph.D. Executive Director, A*STAR BTI

Professor Lam Kong Peng is an immunologist by training and is currently the Executive Director of A*STAR’s Bioprocessing Technology Institute (BTI).  He is also Professor of Microbiology & Immunology at the Yong Loo Lin School of Medicine at The National University of Singapore (NUS) and Adjunct Professor at the School of Biological Sciences at Nanyang Technological University (NTU).  Prof Lam is also Vice-President of the Asian Federation of Biotechnology (AFOB) and Vice-President of the Asia-Pacific International Molecular Biology Organisation (A-IMBN).

Tan Soo Yong, M.D. Head of Pathology, NUH

Tan Soo Yong

M.D. Head of Pathology, NUH

A/Prof Tan Soo Yong obtained his medical qualifications from the National University of Singapore and thereafter underwent postgraduate training in Forensic Pathology and Histopathology in Singapore and in the University of Sheffield, United Kingdom. Qualifying in both forensic and histopathology, he is a Fellow of the Royal College of Pathologists (UK) and a Diplomate of the Society of Apothecaries of London. A/Prof Tan obtained his PhD from Oxford University, working in the field of haematopathology. He holds multiple concurrent appointments as Senior Consultant to the Ministry of Health Singapore, Visiting Consultant to the National Skin Centre and National Cancer Centre Singapore, Head of the Advanced Molecular Pathology Laboratory (AMPL) and Senior Principal Investigator at the Institute of Cell and Molecular Biology (IMCB).

Our Partners

Clinical Research Partners

Government Agencies